The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments [NR2-peptide] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.
- Observation: Case-Only
- Perspective: Prospective
- Sampling: Probability Sample
Patients admitted with symptoms suspicious of acute hemispheric stroke to primary, secondary and tertiary care hospitals in Europe.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage)||9 months||No|
Biospecimen Retention:Samples Without DNA - Human plasma